Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan.
Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan.
Vaccine. 2021 Feb 12;39(7):1131-1139. doi: 10.1016/j.vaccine.2021.01.008. Epub 2021 Jan 18.
Antigen (Ag) delivery to lymphoid follicles is important in achieving adaptive immunity. We recently developed a novel two-step Ag delivery system that efficiently induces cellular immune responses to Ags in mice by using priming intravenous (i.v.) injections of empty PEGylated liposomes (PEG-Lip) followed 3 days later by Ag-entrapped PEG-Lip (Ag-PEG-lip). In this study, we looked for humoral immune responses in rats and mice with IgG production specific to the encapsulated Ags. We observed that initial i.v. injections of empty PEG-Lip triggered accumulation of subsequent doses ovalbumin-PEG-Lip (OVA-PEG-lip) in splenic follicles and enhanced IgG production against OVA in both rats and mice. Anti-OVA IgG production was diminished by inhibition of splenic follicular accumulation of OVA-PEG-Lip by fingolimod (FTY720), which inhibits lymphocyte egress from lymphoid tissues. Thisindicates that the follicular accumulation of Ags that we observed is an indispensable and unique step in the production of anti-OVA IgG. Interestingly, in BALB/c nude mice, which are T cell deficient, a high follicular accumulation of OVA-PEG-Lip was observed, but anti-OVA IgG production was not observed. This suggests that T cells are also indispensable for the induction of cellular immune responses by our two-step immunization procedure. Our unique Ag delivery platform, which efficiently delivers Ags to splenic follicles, may be a useful technique for the enhancement of cellular immunity, as well as humoral immunity. Further experimental evaluation should be undertaken in relevant animal models in order for efficacy, safety and immunological correlates to be determined.
抗原 (Ag) 递送至淋巴滤泡对于获得适应性免疫至关重要。我们最近开发了一种新的两步 Ag 递呈系统,该系统通过在 3 天前用空 PEG 化脂质体 (PEG-Lip) 进行初始静脉内 (i.v.) 注射,然后用包裹 Ag 的 PEG-Lip (Ag-PEG-lip) 进行后续注射,可有效地在小鼠中诱导针对 Ag 的细胞免疫反应。在这项研究中,我们在大鼠和小鼠中寻找针对包裹 Ag 的 IgG 产生的体液免疫反应。我们观察到,初始 i.v. 注射空 PEG-Lip 可触发后续剂量卵清蛋白 PEG-Lip (OVA-PEG-lip) 在脾脏滤泡中的积聚,并增强大鼠和小鼠对 OVA 的 IgG 产生。用 fingolimod (FTY720) 抑制 OVA-PEG-Lip 在脾脏滤泡中的积聚可减弱抗 OVA IgG 的产生,FTY720 可抑制淋巴细胞从淋巴组织中迁出。这表明我们观察到的 Ag 滤泡积聚是产生抗 OVA IgG 的不可或缺和独特步骤。有趣的是,在 T 细胞缺乏的 BALB/c 裸鼠中,观察到 OVA-PEG-Lip 的高滤泡积聚,但未观察到抗 OVA IgG 的产生。这表明 T 细胞对于我们两步免疫程序诱导细胞免疫反应也是不可或缺的。我们的独特 Ag 递呈平台可有效地将 Ag 递送至脾脏滤泡,可能是增强细胞免疫和体液免疫的有用技术。为了确定疗效、安全性和免疫相关性,应在相关动物模型中进一步进行实验评估。